Drug Trial Radar · NCT04183764
MAX-40279-01 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jan 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 28, 2019
Primary completion
Nov 1, 2022
Study completion Dec 1, 2022
Sponsor
- Lead sponsor
- Maxinovel Pty., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 3, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with advanced solid tumor.
Conditions
- Solid Tumor
Interventions
MAX-40279-01Drug
Part 1: Dose escalation, MAX-40279-01 twice daily with dose modifications based on tolerability criteria. Part 2: Dose expansion, Recommended doses from Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD)Time frame: 4 weeks
- Adverse events (AEs)Time frame: 8 weeks
- Phase II dose (RP2D)Time frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.